Research
Hormonal
Meta-regression suggested no significant correlation between BP reduction and baseline characteristics such as age, gender, HbA1c, weight, BMI, and percentage of patients with hypertension.
GLP-1 receptor agonists may be effective for BP management regardless of certain baseline characteristics.
StrongQualifiesmedium confidence
Meta-regression suggested no significant correlation between BP reduction and baseline characteristics such as age, percentage of male patients, HbA1c, weight, BMI, and percentage of patients with hypertension.
Why this rating
Derived from a comprehensive meta-regression analysis.
Source
Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials
Hon Jen Wong et al. · Journal of Hypertension · 2024
DOI 10.1097/hjh.0000000000003903
Meta-analysisCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists demonstrated a mean systolic BP reduction of -3.37 mmHg and a mean diastolic BP reduction of -1.05 mmHg compared with placebo.Strong
- The BP reduction effect of GLP-1 RAs was consistent across subgroups for diabetic status, formulation, follow-up duration, and route of administration.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →